Literature DB >> 1315372

Immunoglobulin G subclasses and lymphocyte stimulatory responses to cytomegalovirus in transplant patients with primary cytomegalovirus infections.

T Mathiesen1, C Brattström, J Andersson, A Linde, P Ljungman, B Wahren.   

Abstract

The early activation of T- and B-cell responses to cytomegalovirus was studied in immunosuppressed patients. Primary lymphocyte stimulation to cytomegalovirus (CMV) antigen, a measure of T-helper activity, and anti-CMV IgG subclass responses were analyzed. Ten patients suffering from primary CMV infection following renal transplantation were studied. Of the ten, nine became positive for CMV induced lymphocyte proliferation 5-40 weeks after transplantation. Nine showed an almost simultaneous appearance of anti-CMV IgG1 and three at 3-32 weeks after transplantation, while one patient synthesized only low levels of anti-CMV IgG1. The lymphocyte proliferation assays have limited diagnostic value for primary CMV infection in renal transplant patients. The humoral and cellular immune responses seemed to be independent of each other.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1315372     DOI: 10.1002/jmv.1890360113

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  3 in total

Review 1.  Bloodstream infections after solid-organ transplantation.

Authors:  Antonios Kritikos; Oriol Manuel
Journal:  Virulence       Date:  2016-01-14       Impact factor: 5.882

2.  Comparison of immunoglobulin G subclass profiles induced by measles virus in vaccinated and naturally infected individuals.

Authors:  María Beatríz Isa; Laura Martínez; Miguel Giordano; Carlos Passeggi; María Cristina de Wolff; Silvia Nates
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

3.  Measles virus-specific immunoglobulin G isotype immune response in early and late infections.

Authors:  M B Isa; L Martínez; M Giordano; M Zapata; C Passeggi; M C De Wolff; S Nates
Journal:  J Clin Microbiol       Date:  2001-01       Impact factor: 5.948

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.